For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
The SYNERGY BP Stent demonstrated the numerically lowest stent thrombosis rates compared to other DES, despite being used in patients with more complex disease.1 The SCAAR registry is a national, 20-hospital registry of data relating to stent performance in Sweden.
Low Event Rates after Early DAPT Discontinuation in Complex Patients2
In a retrospective, single-center analysis of 100 extremely complex patients from Belfast, Ireland, the use of the SYNERGY stent allowed for early discontinuation of DAPT, without an increase in the incidence of stent thrombosis, MI and cardiac death at 12 Months.
The SYNERGY Stent’s real-world evidence shows positive outcomes in complex groups of patients, and the option to discontinue DAPT if the need arises.